Original Articles
1. Burda CD, Sanders CV: Chronic post-rheumatic fever (Jaccoud's) arthritis. Arch
Intern Med 120:712-216, 1967.
2. Sanders CV, Hahn R: Analysis of 106 cases of tularemia. J La State Med
Soc 120:391-393, 1968.
3. Luby JP, Sanders CV: Green monkey disease ("Marburg virus"
disease): A new zoonosis. Ann Intern Med 71:657-659, 1969.
4. Sanders CV, Luby JP, Johanson WG, Barnett JA, Sanford JP, Pierce AK: Serratia
marcescens infections from inhalation
therapy medications: Nosocomial outbreak. Ann Intern Med 73:15-21, 1970.
5. Luby JP, Sanders CV, Sulkin SE: Interferon assays and quantitative virus
determinations in a fatal infection in man with western equine
encephalomyelitis virus. Am J Trop Med Hygiene 60:765-769, 1971.
6. Allison FA Jr., Sanders CV: The extragenital manifestations of gonococcal
infection. South Med Bull ,
59:38-44, 1971.
7. Sanders CV, Luby JP, Sanford JP, Hull AR: Suppression of interferon response
in lymphocytes from patients with uremia. J Lab Clin Med 77:768-776, 1971.
8. Hargrove MD, Sanders CV: Extreme elevation in total serum bilirubin: A study
of the causes in 32 consecutive cases. South Med J 64:213-217, 1971.
9. Luby JP, Sanders CV, Johanson WG, McCubbin JH, Barnett JA, Sanford JP:
Trinity River serologic survey: A survey of residents of communities along the
course of the Trinity River between Houston and Dallas, Texas, for antibodies
to the viruses of St. Louis encephalitis, western equine encephalitis and
California encephalitis. Am J Epidemiol 94:479-486, 1971.
10. Gilbert DN, Sanford JP, Kutscher E, Sanders CV, Luby JP, Barnett JA: Microbiologic
study of wound infections in tornado casualties. Arch Environ Health 26:125-130, 1973.
11. Glancy DL, Sanders CV, Porta A: Posterior chest wall pulsation in
congenital complete absence of the left pericardium. Chest 65:564-566, 1974.
12. Sanders CV: Prescribing for upper respiratory infections. Monograph
prepared for patient care projects, 1976.
13. Sanders CV, Saenz RE, Lopez M: Splinter hemorrhages and onycholysis:
Unusual reactions associated with tetracycline hydrochloride therapy. South
Med J 69:1090-1092, 1976.
14. Brown JW, Nadell J, Sanders CV, Sardenga L: Brain abscess caused by Cladosporium
trichoides (bantianum) : A case with
paranasal sinus involvement. South Med J 69:1519-1521, 1976.
15. Repath F, Seabury JH, Sanders CV, Domer J: Prosthetic valve endocarditis
due to Mycobacterium chelonei . South
Med J 69:1244-1246, 1976.
16. Mackowiak PA, Sanders CV, Thomason J: Acute meningococcemia without
meningitis in association with influenza-like illness. South Med J 69:222-224, 1976.
17. Bracis R, Sanders CV, Gilbert DN: Methicillin hemorrhagic cystitis. Antimicrob
Agents Chemother 12:438-439, 1977.
18. Torres JR, Sands M, Sanders CV: In vitro sensitivity of Mycobacterium
marinum to minocycline and doxycycline. Tubercle 59:193-195, 1978.
19. Greenberg RN, Brooks BJ, Sanders CV: The isolated case of Legionnaires'
disease. South Med J
71:1141-1144, 1978.
20. Torres JR, Sanders CV, Strub RL, Black W: Cat-scratch disease causing
reversible encephalopathy. JAMA
240:1628-1629, 1978.
21. Greenberg RN, Eversmeter WH, Sanders CV: Hepatitis B presenting with
tenosynovitis. South Med J
72:375-376, 1979.
22. Greenberg RN, Scalcini MC, Sanders CV, Lewis AC: Cefamandole therapy in
anaerobic infections. Antimicrob Agents Chemother 15:337-341, 1979.
23. Bryan CS, Huffman LJ, Del Bene VE, Sanders CV, Scalcini MC: Intravenous
metronidazole therapy for Bacteroides fragilis meningitis. South Med J 72:494-497, 1979.
24. Greenberg RN, Sanders CV: Typhoid fever: A public health concern. JCE
Clin Med 25:16-22, 1979.
25. Klein RC, Sanders CV, Cook EW: Anaerobic lung infections. JCE
Clin Med 25:24-31, 1979.
26. Torres-R JR, Maki NJ, Taddonio RF, Sanders CV: Cutaneous rhizophus
infection associated with elastoplast wound dressing. Orthopedics 2:384-386, 1979.
27. Sanders CV, Hanna BJ, Lewis AC: Metronidazole in the treatment of anaerobic
infections. Am Rev Resp Dis
120:337-343, 1979.
28. Torres-R JR, Taddonio RF, Sanders CV: Spondylitis caused by Brucella
abortus . South Med J 72:1166-1169, 1979.
29. Torres-R JR, Sanders CV, Lewis AC: Vancomycin concentration in human
tissues-preliminary report. J Antimicrob Chemother 5:475-477, 1979.
30. Greenberg RN, James RB, Marier RL, Wood WH, Sanders CV, Kent JN:
Microbiologic and antibiotic aspects of infections in the oral and
maxillofacial region. J Oral Surg
37:873-884, 1979.
31. Sanders CV, Hanna BJ, Lewis AC, Scalcini M: The use of metronidazole in the
treatment of anaerobic pleuropulmonary infections. Proceedings of the
Second International Symposium on Anaerobic Infections , Geneva, Switzerland, April 25-27, 1979.
International Congress and Symposium Series, No. 18, The Royal Society of
Medicine, New York, Grune & Stratton, 1979.
32. Sanders CV, Bourge RC: When and how to use the new cephalosporins. Contemp
Ob Gyn 14:67-77, 1979.
33. Torres-R JR, Sanders CV: Guidelines for using aminoglycosides. Contemp
Ob Gyn 14:39-47, 1979.
34. Scalcini MC, Sanders CV: Endocarditis from human-to-human transmission of Staphylococcus
aureus . Arch Intern Med 140:111-112, 1980.
35. Sanders CV: Treating anaerobic infection in the 1980's. Contemp
Ob Gyn 15:69-89, 1980.
36. Sanders CV: The aminoglycosides: An overview. Syva Monitor , No. 6, pp 1-8, May, 1980.
37. Greenberg RN, Scalcini MC, Sanders CV, Lewis AC: The treatment of serious
anaerobic infections. Scan J Infect Dis , Suppl 25:84-88, 1980.
38. Torres-R JR, Sanders CV, Swenson RM, Hanna B, Lorber B, Lewis AC: Treatment
of anaerobic infections with ticarcillin: Clinical and laboratory results. Curr
Ther Res 30:528-534, 1981.
39. Greenberg RN, Sanders CV, Lewis AC, Marier RL: Single dose cefaclor therapy
of urinary tract infection: Evaluation of antibody coated bacteria tested and
C-reactive protein assay as predictors of cure. Am J Med 71:841-845, 1981.
40. Torres-R JR, Stratton CW, Sanders CV, et al: Candidal suppurative
peripheral thrombophlebitis. Ann Intern Med 96:431-435, 1982.
41. Martin DA, Sanders CV, Marier RL: N-formimidoyl thienamycin (MK0787): In
vitro activity against anaerobic bacteria. Antimicrob Agents
Chemother 21:168-169, 1982.
42. Derks FW, Sanders CV, Marier RL: Choosing initial antimicrobial therapy. Consultant 22:117-129, 1982.
43. Marier RL, Marinaccio AT, Sanders CV, Aldridge KE, Mitchell JW:
Susceptibility patterns of bacteria following therapy with piperacillin. J
Antimicrob Chemother 9(Suppl B):85-91,
1982.
44. Marier RL, Aldridge KE, Sanders CV: The role of anaerobes in sinus and
middle ear infections--implications for the future. Proceedings of
the First United States Metronidazole Conference , S Finegold (ed), pp 345-356, Biomedical Information Corporation,
1982.
45. Sanders CV, Aldridge KE, Marier RL: Diagnosis of anaerobic infections. Proceedings
of the First United States Metronidazole Conference , S Finegold (ed), pp 11-23, Biomedical Information Corporation, 1982.
46. Marier RL, Faro S, Sanders CV, Williams WL, Derks FW, Janney A, Aldridge
KE: Moxalactam in the therapy of serious infection. Antimicrob Agents
Chemother 21:650-654, 1982.
47. Marier RL, Sanders CV, Faro S, Janney A, Williams WL, Derks FW, Aldridge
KE: Piperacillin versus carbenicillin in the therapy for serious infections. Arch
Intern Med 142:2000-2005, 1982.
48. Korzeniowski OM, Sande MA, National Collaborative Endocarditis Study Group
(including CV Sanders): Combination antimicrobial therapy of Staphylococcus
aureus endocarditis in patients addicted to
parenteral drugs and in nonaddicts: A prospective study. Ann Intern
Med 97:496-503, 1982.
49. Faro S, Sanders CV, Aldridge KE: Use of single agent antimicrobial therapy
in the treatment of polymicrobial female pelvic infections. Obstet
Gynecol 60:232-236, 1982.
50. Brooks BJ Jr., Marier R, Sanders CV: Ulcer of the hard palate. JAMA 247:819-820, 1982.
51. Franklin RM, Bond W, Sanders CV, Joffe L: Presumed blastomycosis
endophthalmitis. Ann Ophthal
14:1183-1188, 1982.
52. Jain A, Sanders CV, Nicholle FI: Drug fever during treatment of pulmonary
edema. South Med J 75:1140-1141,
1982.
53. Brooks BJ, Williams WL, Sanders CV, Marier RL: Apparent ketoconazole
failure in candidal cholecystitis. Arch Intern Med 142:1934-1935, 1982.
54. Aldridge KE, Sanders CV, Lewis AC, Marier RL: Susceptibility of anaerobic
bacteria to beta-lactam antibiotics and beta-lactamase production. J
Med Microbiol 16:75-82, 1983.
55. Chambers HF, Korzeniowski OM, Sande MA, with the National Collaborative
Endocarditis Study Group (including CV Sanders): Staphylococcus
aureus endocarditis: Clinical
manifestations in addicts and nonaddicts. Medicine 62:170-177, 1983.
56. Wickboldt LG, Sanders CV: Vibrio vulnificus infection: Case report and update since 1970. J
Am Acad Dermatol 9:243-251, 1983.
57. Sanders CV, Aldridge KE: The microbiology lab: Garbage in, garbage out. Clin
Micro Newsletter V5(18), September 15,
1983.
58. Bordelon JY, Legrand P, Gewin WC, Sanders CV: The telescoping plugged
catheter in suspected anaerobic infections: A controlled series. Am
Rev Resp Dis 128:465, 1983.
59. Aldridge KE, Janney A, Sanders CV, Marier RL: Interlaboratory variation of
antibiograms of methicillin-resistant and methicillin-susceptible Staphylococcus
aureus strains with conventional and
commercial testing systems. J Clin Micro 18:1226-1236, 1983.
60. Sanders CV: Anaerobic infections. Turning Points in Infection , No. 3, Lederle Laboratories, Wayne, New Jersey,
1983.
61. Marier RL, McCloskey RV, Dickenson G, Sanders CV, Aldridge KE, Hoffman T,
Gutterman D, Janney A: Comparative clinical trial of imipenem-cilastatin
(N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin. J
Antimicrob Chemother 12(Suppl D): 133-139,
1983.
62. Karam GH, Sanders CV: Acute sinusitis. Dial Access Program. Southern
Medical Association, 1984.
63. Karam GH, Sanders CV: Subacute and chronic sinusitis. Dial Access Program.
Southern Medical Association, 1984.
64. Derks FW, Sanders CV, Marier RL: Anaerobic infections: a guideline for
choosing antibiotics. Consultant
, January:206-226, 1984.
65. Aldridge KA, Kogos C, Sanders CV, Marier RL: Comparison of rapid
identification assays for Staphylococcus aureus . J Clin Microbiol 19:703-704, 1984.
66. Aldridge KE, Sanders CV, Janney A, Faro S, Marier RL: In vitro synergy and
potentiation between cefotaxime and desacetylcefotaxime against clinical
isolates of Bacteroides . Diag
Microbiol Inf Dis 2:47S-53S, 1984.
67. Aldridge KE, Sanders CV, Janney A, Faro S, Marier RL: Comparison of the
activities of penicillin G and new beta-lactam antibiotics against clinical
isolates of Bacteroides species. Antimicrob
Agents Chemother 26:410-413, 1984.
68. Sanders CV, Greenberg RN, Marier RL: Cefamandole and cefoxitin. Ann
Intern Med 103:70-78, 1985.
69. Aldridge KE, Schiro D, Tsai L, Janney A, Sanders CV, Marier RL:
Ciprofloxacin (Bay o 9867): An in vitro comparison with other broad spectrum
antibiotics. Curr Ther Res 37:754-762,
1985.
70. Sanders CV, Marier RL, Aldridge KE, Derks FW, Martin DH: The safety and
effectiveness of ticarcillin/clavulanic acid in the treatment of
community-acquired acute pyelonephritis in adult women. Am J Med 79(suppl 5B):96-100, 1985.
71. Aldridge KE, Janney A, Sanders CV: Comparison of the activity of
coumermycin, ciprofloxacin, teicoplainin, and other non-beta-lactam antibiotics
against clinical isolates of methicillin-resistant Staphylococcus
aureus from various geographical locations.
Antimicrob Agents Chemother
28:634-638, 1985.
72. Kumar P, Bentley FR, Leech SH, Sanders CV: Accidental administration of
hepatitis B immune globulin to a patient positive for hepatitis B surface
antigen. Ann Allergy 55:683-685,
1985.
73. Aldridge KE, Tsai L, Sanders CV: Comparative activity of ciprofloxacin (BAY
o 9867) with beta-lactam antibiotics and gentamicin, and the effect of inoculum
size, against aerobic gram positive and -negative bacteria. Proceedings
of the 14th International Congress of Chemotherapy , Kyoto, Japan, June 23-28, 1985. Recent Advances in Chemotherapy
Antimicrobial Section, University of Tokyo Press, pp 1559-1560, 1985.
74. Aldridge KE, Sanders CV: Increased in vitro anti-Bacteroides activity of cefotaxime: synergistic interaction of cefotaxime
and desacetylcefotaxime. Recent Advances in Chemotherapy:
Antimicrobial Section , University of Tokyo
Press, pp 606-607 Proceedings of the 14th International Congress of
Chemotherapy, Kyoto, Japan, June 23-29, 1985.
75. Besch CL, Sanders CV: Managing sepsis--a common cause of geriatric death. Geriatrics 41:55-66, 1986.
76. Aldridge KE, Sanders CV, Marier RL: Variation in the potentiation of
B-lactam antibiotic activity by clavulanic acid and sulbactam against multiply
antibiotic-resistant bacteria. Antimicrob Agents Chemother 17:463-469, 1986.
77. Zide MF, Sanders CV, Marier RL, Aldridge KE, Derks FW: Cefuroxime therapy
for maxillofacial infections. Curr Ther Res 40:278-287, 1986.
78. Aldridge KE, Sanders CV: Comparison of the activity of carumonam (RO
17-2301) with other broad-spectrum antibiotics: In vitro antibacterial
spectrum, inoculum effect, and synergy studies. Curr Ther Res 40:515-527, 1986.
79. Aldridge KE, Sanders CV: Comparison of the activity of cefpirome (HR 810),
a new cephalosporin, to other beta-lactam against clinical isolates of Streptococcal
agalactiae . Curr Ther Res 40:1069-1077, 1986.
80. Aldridge KE, Schiro DD, Sanders CV: Pefloxacin (RB 1589): An in vitro
comparison with other oral antimicrobial agents and imipenem. Curr
Ther Res 40:1103-1113, 1986.
81. Besch CL, Sanders CV: Managing sepsis--a common cause of geriatric death. Geriat
Dig 8:29-30, 1986.
82. Sanders CV, Derks FW: Drugs as a cause of unexplained fever. Modern
Medicine 55:72-77, 1987.
83. Aldridge KE, Schiro DD, Sanders CV: RO23-6240, a new absorbed quinolone: In
vitro comparison with other broad-spectrum oral antimicrobial agents and
imipenem. Diagn Microbiol Infect Dis
7:9-19, 1987.
84. Saenz C, Sanders CV, Nguyen BP, Reisin E: Macronodular lesions associated
with Staphylococcal aureus
bacteremia: A condition that resembles a 'lymphocutaneous' syndrome. Arch
Intern Med 147:793, 1987.
85. Aldridge KE, Schiro DD, Sanders CV: Comparative in vitro activity of new
oral cephalosporin BMY-28100. Eur J Clin Microbiol 6:170-172, 1987.
86. Aldridge KE, Schiro DD, Sanders CV: Comparative in vitro activity of the
two new oral cephalosporin metabolites RO 19-5247 and RO 15-8074. Eur
J Clin Microbiol 6:564-569, 1987.
87. Aldridge KE, Sanders CV: Antibiotic- and method-dependent variation in
susceptibility testing results of Bacteroides fragilis group isolates. J Clin Microbiol 25:2317-2321, 1987.
88. Sanders CV: Comparative in vitro activity of ciprofloxacin, norfloxacin,
ofloxacin, B-lactam antibiotics, and gentamicin against aerobic gram-positive
cocci and gram-negative bacilli. Rev Infect Dis 10(S1):S42, 1987
89. Sanders CV: Role of newer antimicrobials in the treatment of mixed
aerobic/anaerobic infections (monograph). Therapeutic Advances in the
Treatment of Infectious Diseases .
Pragmaton Publications, Chicago, Illinois, 1987.
90. Hill MK, Sanders CV: Localized and systemic infections due to vibrio
species. Inf Dis Clin NA
1:687-707, 1987.
91. Bone RC, Fisher CJ Jr., Clemmer TP, Slotman GJ, Metz CA, Methylprednisolone
Severe Sepsis Study Group (including CV Sanders): Early methylprednisolone
treatment for septic syndrome and the adult respiratory distress syndrome. Chest
92:1032-1036, 1987.
92. Bone RC, Fisher CJ Jr., Clemmer TP, Slotman GJ, Metz CA, Balk RA, Methylprednisolone
Severe Sepsis Study Group (including CV Sanders): A controlled clinical trial
of high-dose methylprednisolone in the treatment of severe sepsis and septic
shock. N Engl J Med 317:653-658,
1987.
93. Bartlett JG, Ledger WJ, Sanders CV: A site-by-site attack on anaerobes. Patient
Care March 30, 1987.
94. Aldridge KE, Sanders CV: Pefloxacin, a new fluorinated quinolone:
Comparison of its in vitro activity with that of other broad-spectrum
antibiotics. Rev Infect Dis
10(S1):S40-S41, 1988.
95. Hill MK, Sanders CV: Principles of antimicrobial therapy for head and neck
infections. Inf Dis Clin NA
2:57-83, 1988.
96. Sanders CV, Pastorek JG, Miller JM, Aldridge KE: Ticarcillin disodium and
clavulanate potassium in the treatment of post-cesarean-section
endomyometritis. J Reprod Med 33
(Suppl):584-587, 1988.
97. Dudley MN, Neu HC, Pankey GA, Sanders CV, Sweet RL: Roundtable discussion:
Use of B-lactamase inhibitors in antibiotic therapy: AP&T Committee review
of ampicillin/sulbactam. Hosp Formul
23(Supp1A):9-14, 1988.
98. Sanders CV, Pastorek JG, Miller JM, Aldridge KE: Ticarcillin disodium and
clavulanate potassium in the treatment of post-caesarian section
endomyometritis. J Reprod Med
33(6S):584-590, 1988.
99. Aldridge KE, Henderberg A, Schiro DD, Sanders CV: Susceptibility of Bacteroides
fragilis group isolates to broad spectrum
beta-lactams clindamycin and metronidazole: Rates of resistance,
cross-resistance, and importance of beta-lactamase production. Advan
Ther 5:273-282, 1988.
100. Aldridge KE, Valainis GT, Sanders CV: Comparison of the in vitro activity
of ciprofloxacin and 24 other antimicrobial agents against clinical strains of Chromobacterium
violaceum . Diag Microbiol Inf
Dis 10:31-39, 1988.
101. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA,
Methylprednisolone Severe Sepsis Study Group: The sepsis syndrome: A valid
clinical entity. Crit Care Med
17:389-393, 1989.
102. Aldridge KE, Weeks LS, Stratton CW, Sanders CV: Comparison of the
bactericidal activity of cefotaxime and desacetylcefotaxime alone and in
combination against Bacteroides fragilis group organisms. Diagn Microbiol Inf Dis 12:165-170, 1989.
103. Aldridge KE, Henderberg A, Sanders CV: Lomefloxacin, a new
fluoroquinolone: studies on in vitro antimicrobial spectrum, potency, and
development of resistance. Diagn Microbiol Inf Dis 12:221-233, 1989.
104. Champagne KJ, Sanders CV, Hastings PR: Aeromonas hydrophila in water and soil contaminated injuries. Infect
Med Jan/Feb:19-25; 1989.
105. Fan Y-D, Pastorek JG, Janney FA, Sanders CV: Listeriosis as an obstetric
complication in an immunocompromised patient. South Med J 82:1044-1045, 1989.
106. Risi GF, Gaumer R, Weeks S, Leete J, Sanders CV: Human immunodeficiency
virus: risk of exposure among health care workers at a southern U.S. urban
hospital. South Med J 82:1079-1082,
1989.
107. Aldridge KE, Henderberg A, Sanders CV: Lomefloxacin (SC 47111 or NY-198),
a new difluorinated quinolone: Comparison of the in vitro activity with other
broad spectrum antimicrobials against Enterobacteriaceae,
Acinetobacter spp, Aeromonas spp, and Pseudomonas aeruginosa . Diagn Microbiol Inf Dis 12:1S-6S, 1989.
108. Aldridge KE, Henderberg A, Gebbia K, Schiro DD, Janney A, Sanders CV:
Lomefloxacin, a new fluoroquinolone: Studies on in vitro antimicrobial
spectrum, potency, and development of resistance. Diagn Microbiol
Infect Dis 12:221-233, 1989.
109. Champagne KJ, Sanders CV, Hastings PR: Aeromonas hydrophila in water and soil contaminated injuries. Infections
in Surgery: Epidemiology of Inf
April:139-142, 1989.
110. Aldridge KE, Henderberg A, Sanders CV: Mutational frequency of
gram-positive and gram-negative bacteria to resistance to lomefloxacin and
other quinolones. Rev Infect Dis
11(Suppl 5):S974-S975, 1989.
111. Risi GF, Sanders CV: The genital mycoplasmas. Obstet Gynecol
Clin NA 16:611-626, 1989.
112. Aldridge KE, Henderberg A, Sanders CV: In vitro activity of lomefloxacin
against gram-positive and gram-negative bacteria. Rev Infect Dis 11:S935, 1989.
113. Wallace RJ Jr., Bedsole G, Sumpter G, Sanders CV, et al: Activities of
ciprofloxacin and ofloxacin against rapidly growing mycobacteria with
demonstration of acquired resistance following single-drug therapy. Antimicrob
Agents Chemother 34:65-70, 1990.
114. Aldridge KE, Wexler HM, Sanders CV, Finegold SM: Comparison of in vitro
antibiograms of Bacteroides fragilis
group isolates: differences in resistance rates in two institutions because of
differences in susceptibility testing methodology. Antimicrob Agents
Chemother 34:179-181, 1990.
115. Aldridge KE, Henderberg A, Sanders CV: Susceptibility of
cefoxitin-resistant Bacteroides fragilis group strains to other beta-lactam and non-beta-lactam antimicrobials.
Advan Ther 7:16-21, 1990.
116. Aldridge KE, Henderberg A, Schiro DD, Sanders CV: Discordant results
between the broth disk elution and broth microdilution susceptibility tests
with Bacteroides fragilis group
isolates. J Clin Micro
28:375-378, 1990.
117. Sanders CV and Aldridge KE: In vitro anaerobic data on ticarcillin/clavulanate.
A review of an ongoing survey. J Reprod Med 35:313-316, 1990.
118. Aldridge KE, Henderberg A, Sanders CV: In-vitro study of the
susceptibility of cefoxitin/cefotetan resistance Bacteroides fragilis group strains to various other antimicrobial agents.
J Antimicrob Chemother
26:353-359, 1990.
119. Aldridge KE, Weeks LS, Stratton CW, Sanders CV: Differences in the in
vitro inhibitory and bactericidal activity of ceftizoxime, cefoxitin,
cefotetan, and penicillin G against Bacteroides fragilis group isolates: Comparison of time-kill kinetic
studies with MIC values. Diagn Microbiol Infect Dis 13:311-316, 1990.
120. Aldridge KE, Wexler HM, Sanders CV, Finegold SM: Comparison of in vitro
antibiograms of Bacteroides fragilis
group isolates: Differences in resistance rates in two institutions because of
differences in susceptibility methodology. Antimicrob Agents
Chemother 34:179-181, 1990.
121. Greenman RL, Schein RMH, Martin MA, et al, and the Xoma Sepsis Study
Group: A controlled clinical trial of E5 murine monoclonal IgM antibody to
endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097-1102, 1991.
122. Hill MK, Sanders CV: Tuberculosis in pregnancy. Contemp OB/GYN 36:104-110, 1991.
123. Pastorek JG II, Sanders CV: Antibiotic therapy for post-caesarean
endomyometritis. Rev Infect Dis
13:S752-S757, 1991.
124. Sanders CV, Aldridge KE: Antimicrobial therapy of anaerobic
infections--1991. Pharmacother
II:72S-79S, 1991.
125. Karam GH, Sanders CV, Aldridge KE: Role of newer antimicrobial agents in
the treatment of mixed aerobic and anaerobic infections. Surg Gynecol
Obstet 172(Suppl):57-64, 1991.
126. Hill MK, Sanders CV: Anaerobic disease of the lung. Infect Dis
Clin NA 5:453-466, 1991.
127. Rodriguez MC, Musher DM, Hamill RJ, Dowell M, Bagwell JT, Sanders CV:
Unusual manifestations of pneumococcal infection in human immunodeficiency
virus-infected individuals: The past revisited. CID 14:192-199, 1992.
128. Sanders CV, Aldridge KE: Current antimicrobial therapy of anaerobic
infections. Eur J Clin Microbiol & Infect Dis 11:999-1011, 1992.
129. Marier RL, Sanders CV, Aldridge KE: Treatment of polymicrobial infections.
Proceedings of an International Conference: Advances in
Beta-Lactamase-Inhibitor Combination Therapy: A Perspective in Piperacillin/Tazobactam
in Surgery, São Paulo, Brazil. Complications in Surgery 12 (Suppl A):70-76, 1993.
130. Sanders CV, Hill MK: Vibrio vulnificus . Infect Dis Prac 17:1-4, May 1993.
131. Aldridge KE, Gelfand M, Reller LB, Ayers LW, Pierson CL, Schoenknecht F,
Tilton RC, Wilkins J, Henderberg A, Schiro D, Johnson M, Janney A, Sanders CV:
A five-year multicenter study of the susceptibility of the B.
fragilis group isolates to cephalosporins,
cephamins, penicillins, clindamycin, and metronidazole in the United States. Diagnost
Microbiol Infect Dis 18:235-241, 1994.
132. Sanders CV: Respiratory RX: New broad spectrum agent addresses beta-lactam
resistance. Advance Managers Resp Care 3:39-40, March 1994.
133. Sanders CV Jr.: Piperacillin/tazobactam in the treatment of
community-acquired and nosocomial respiratory tract infections: a review. Intens
Care Med 2:S21-S26, 1994.
134. Hill MK, Sanders CV: Polymicrobial infections. Ochsner Clinic
Reports on Serious Hospital Infections
6:1-8, 1994.
135. Sanders CV: Treatment of polymicrobial gynecologic and skin and
skin-structure infections: worldwide clinical trials. Piperacillin/Tazobactam:
A New Dimension in Antibiotic Therapy. Infect Dis Clin Prac 4:S26-32, 1995.
136. Hill MK, Sanders CV: Community-acquired pneumonia. Ochsner
Clinic Reports on Serious Hospital Infections
7:1-8, 1995.
137. Hill MK, Sanders CV: Leptospiral pneumonia. Seminars in
Respiratory Infections . 12:44-49, 1997.
Clark RA, Sanders CV. An update on management of persons with human
immunodeficiency virus and acquired immunodeficiency syndrome: introduction to
symposium. Am J Med Sci. 2004 Jul;328(1):1-2.
Butt AA, Aldridge KE, Sanders CV. Infections related to the ingestion of
seafood. Part II: parasitic infections and food safety.Lancet Infect Dis. 2004
May;4(5):294-300. Review. Erratum in: Lancet Infect Dis. 2005 Feb;5(2):81.
Butt AA, Aldridge KE, Sanders CV. Infections related to the ingestion of
seafood Part I: Viral and bacterial infections. Lancet Infect Dis. 2004
Apr;4(4):201-12. Review.
Kruspe R, Lillis R, Daberkow DW 2nd, Blais CM, Wilbright W, Gupta S, Gould
CA, Sun T, Martinez JA, deBoisblanc B, Ladabaum U, Sanders CV, Lopez FA. Education
does pay off: pneumococcal vaccine screening and administration in hospitalized
adult patients with pneumonia. J La State Med Soc. 2003 Nov-Dec;155(6):325-31
Aldridge KE, Ashcraft D, O'Brien M, Sanders CV. Bacteremia due to
Bacteroides fragilis group: distribution of species, beta-lactamase production,
and antimicrobial susceptibility patterns. Antimicrob Agents Chemother. 2003
Jan;47(1):148-53.
Lillis RA, Dugan V, Mills T, Berner A 3rd, Sanders CV, Hagensee M, Lopez FA.
A fish hook and liver disease: revisiting an old enemy. J La State Med Soc.
2002 Jan-Feb;154(1):20-5.
Lopez FA, Sanders CV. Dermatologic infections in the immunocompromised
(non-HIV) host. Infect Dis Clin North Am. 2001 Jun;15(2):671-702, xi. Review.
Sanders CV. Memorial Jay P. Sanford 1928-1996. Trans Am Clin Climatol Assoc.
2001;112:xliv-xlvi.
Sanders CV, Lopez FA. Cutaneous manifestations of infectious diseases:
approach to the patient with fever and rash. Trans Am Clin Climatol Assoc.
2001;112:235-51; discussion 251-2.
Slaven EM, Lopez FA, Hart SM, Sanders CV. Myonecrosis caused by Edwardsiella
tarda: a case report and case series of extraintestinal E. tarda infections.Clin
Infect Dis. 2001 May 15;32(10):1430-3.
Saenz RE, Brown WD, Sanders CV. Allergic bronchopulmonary disease caused by
Bipolaris hawaiiensis presenting as a necrotizing pneumonia: case report and
review of literature. Am J Med Sci. 2001 Mar;321(3):209-12. Review.
Fisher WP Jr, Vial RH, Sanders CV. Removing rater effects from medical
clerkship evaluations. Acad Med. 1997 May;72(5):443-4.
Sanders CV. Pneumococcal disease: a symposium in honor of Robert Austrian,
MD--a summary. Am J Med. 1999 Jul 26;107(1A):86S-90S.
Taylor SN, Sanders CV. Unusual manifestations of invasive pneumococcal
infection. Am J Med. 1999 Jul 26;107(1A):12S-27S.
Mendez EA, Espinoza LM, Harris M, Angulo J, Sanders CV, Espinoza LR. Systemic
lupus erythematosus complicated by necrotizing fasciitis. Lupus.
1999;8(2):157-9.
Aldridge KE, Ashcraft DS, O'Cain P, Sanders CV, Janney A, Brown W, Silberman
R, Pankey GK. A multicenter study of the prevalence and susceptibility patterns
of isolates of Streptococcus pneumoniae with reduced susceptibility to
penicillin G in Louisiana. Am J Med Sci. 1998 Oct;316(4):277-84.
Clark RA, Martin DH, Hilton C, Sanders CV. The impact of human
immunodeficiency virus disease on academic health centers. Am J Med. 1998
Aug;105(2):87-90. Review.
Hill MK, Sanders CV. Skin and soft tissue infections in critical care. Crit Care Clin. 1998 Apr;14(2):251-62.
Book
1. Sanders CV, Nesbitt LT (eds.): The Skin in Infection: An Atlas and Text
. Baltimore, Williams & Wilkins, 1995.
Book Chapters
1. Sanders CV: Diagnostic virology. In: Human Diseases Caused by Viruses:
Recent Developments . Rothschild H, Allison R Jr., Howe C (eds.),
New York, NY, Oxford University Press, 1978.
2. Buechner HA, Sanders CV: Preparation of texts for plates on actinomycosis,
nocardiosis, histoplasmosis, North American blastomycosis, South American
blastomycosis, coccidioidomycosis, cryptococcosis, and hypersensitivity
pneumonitis die to the inhalation of organic dust. In: The Civa Collection
of Medical Illustrations: Respiratory System
. Netter FH (ed.), Vol 7 pp 190-198, 216-218, Summitt, NJ, Ciba, 1979.
3. Sanders CV, Torres-R JR: Rational use of the diagnostic virology laboratory.
In: Infectious Diseases: Current Topics . Gilbert DN, Sanford JP (eds.), New York, NY, Grune & Stratton,
pp 107-121, 1979.
4. Sanders CV: Tularemia. In: Tice's Practice of Medicine , Hagerstown, MD, Harper & Row, 1970, Vol 3, pp
1-13; reprinted in Spittel, JA, Jr. (ed.), Clinical Medicine , 1980.
5. Sanders CV, Lewis AC: Changing trends in the antimicrobial susceptibility
pattern of anaerobic bacteria. In: Anaerobic Bacteria: Selected
Topics . Lambe DW Jr., Genco RJ,
Mayberry-Carson KJ (eds.), New York, NY, Plenum, 1981.
6. Sanders CV, Torres-R JR: Tularemia. In: Infectious Diseases . Sanford JP, Luby JP (eds.), New York, NY, Grune
& Stratton, pp 265-268, 1981.
7. Sanders CV, Torres-R JR: Infections due to other pasteurellae and Yersinia.
In: Infectious Diseases . Sanford
JP, Luby JP (eds.), New York, NY, Grune & Stratton, pp 268-270, 1981.
8. Marier RL, Sanders CV: Infectious diseases. In: Family Medicine
Principles and Practice , Taylor RB (ed.),
2nd ed, New York, Springer-Verlag, 1982.
9. Derks FW, Williams WL, Sanders CV, Marier RL: Infectious diseases of the
nervous system. In: Essentials of Clinical Neurology . LA Weisberg, RL Strub, CA Garcia (eds), Baltimore,
MD, University Park Press, pp 305-324, 1983.
10. Sanders CV, Greenberg RN: Ear, nose, and throat infections. In: Clinical
Manual of Infectious Diseases , Rytel MW,
Mogabgab WJ (eds). Chicago, IL, Yearbook Medical Publishers, pp 62-76, 1984.
11. Aldridge KE, Sanders CV, Janney A, Faro S, Marier RL: In vitro synergy and
potentiation between cefotaxime and desacetylcefotaxime against clinical
isolates of Bacteroides . In: New
Concepts of Antimicrobial Interactions with Drug Metabolites and Blood Elements , Jones RN (ed), Amsterdam, The Netherlands,
Excerpta Medica, pp 15-17, 1984.
12. Derks FW, Sanders CV: Rickettsial Diseases. In: Current Diagnosis , RB Conn (ed), 7th ed., Philadelphia, PA, WB
Saunders Company, pp 218-224, 1985.
13. Risi GF, Sanders CV: Anaerobic infections of the urinary tract. In: Anaerobic
Infections in Humans. Finegold SM, George
WL (eds), Florida, Academic Press, Inc., 1988.
14. Derks FW, Sanders CV: Rickettsial diseases. In: Current Diagnosis , RB Conn (ed), 8th ed., Philadelphia, PA, WB
Saunders pp 249-254, 1991.
15. Sanders CV, Hill MK. Tuberculosis in pregnancy. In: Infection
Protocols for Obstetrics and Gynecology ,
Mead PB and Hager WD (eds). Montvale, NJ, Medical Economics Publishing, pp
66-71, 1992.
16. Derks FW, Sanders CV: Antibiotics: The antianaerobic drugs. In: Obstetric
and Gynecologic Infectious Disease ,
Pastorek J.G. (ed). New York, NY, Raven Press, pp 659-665, 1994.
17. Hill MK, Sanders CV: Cutaneous tuberculosis. In: Tuberculosis , 3rd ed. Schlossberg D (ed.) New York, NY,
Springer-Verlag, pp 225-232, 1994.
19. Sanders CV: Approach to the diagnosis of fever and rash. In: The
Skin in Infection: An Atlas and Text ,
Sanders CV, Nesbitt LT (eds.) Baltimore, Williams & Wilkins, pp 296-305,
1995.
20. Hill MK, Sanders CV: Necrotizing and gangrenous soft tissue infections.In: The
Skin in Infection: An Atlas and Text ,
Sanders CV, Nesbitt LT (eds.) Baltimore, Williams & Wilkins, pp 62-75 1995.
Invited Review
1. Sanders CV, reviewer. Cutaneous Manifestations of Infection in the
Immunocompromised Host by Mark Grossman
with Jeffrey Ross. Williams & Wilkins, 1995. Clin Infect Dis 21:461, 1995.
Audio Tapes
1. Sanders CV: A quiz on "Drugs and Bugs." Audio-Digest Family
Practice 29(16), April 27, 1981.
2. Sanders CV: Office use of newer antibiotics. Bugs and Drugs, Highlights of
the American Academy of Family Physician's 40th Annual Scientific Assembly
Audio Digest Foundation, 36(48), 1988.
Correspondence/Letters to the Editor
1. Anderson JH, Sanders CV, Larson P: Exercise myoglobinuria. N Engl J Med 290:632, 1974.
2. Sands M, Sanders CV: Serratia marcescens endocarditis. Ann Intern Med 85:397-398, 1976.
3. Greenberg RM, Sanders CV: Amphotericin B and blastomycosis. South
Med J 71:880-881, 1978.
4. Torres-R JR, Sanders CV, Lewis AC: Vancomycin concentration in human
tissues-- preliminary report. J Antimicrob Chemother 5:475-477, 1979.
5. Greenberg RM, Sanders CV, Stamm WE: Urethral syndrome in women. JAMA 245:923, 1981.
6. Scalcini MC, Sanders CV: Human-to-human transmission of Staphylococcus
aureus endocarditis. Arch Intern
Med 141:546, 1981.
7. Freyberg CW, Sanders CV: Candidal thrombophlebitis. Ann Intern Med 100:463, 1984.
8. Aldridge KE, Sanders CV, Marier RL: Determining the MIC's of B-lactams for Haemophilus . J Antimicrob Chemother 19:441-442, 1987.
9. Bone RC, Metz CA, Fisher CJ Jr., Clemmer TP, Slotman GJ, Goris GB, Balk RA,
the Methylprednisolone Severe Sepsis Study Group: High dose steroids and
sepsis. New Engl J Med
318:514-515, 1988.
10. Aldridge KE, Henderberg A, Sanders CV: Enhanced antimicrobial activity of
old and new B-lactams against cefoxitin-resistant Bacteroides
fragilis group isolates by B-lactamase
inhibitors. J Antimicrob Chemother
25:873-875, 1990.
11. Wykoff RF, Halsey N, et al: The effectiveness of voluntary self-exclusion
on blood donation practices of individuals at high risk for acquired
immunodeficiency syndrome (AIDS). Accepted for publication JAMA
12. Sanders CV, Strong J: LSU would continue Charity system cooperation. The
Times-Picayune , New Orleans, Louisiana,
June 11, 1995.
Editorials
1. Sanders CV, Brown JW: Mycobacterium marinum infections: A problem of recognition, not therapy. Arch
Intern Med 147:817-818, 1987.
Publications in preparation, submitted, accepted, or in press:
1. Soto LF and Sanders CV: Acinetobacter community-acquired pneumonia report of
5 cases and review of the literature. Reviews of Infectious Diseases. Accepted
for publication.
2. Mahatma M, Haponik EF, Klein R, and Sanders CV: Anaerobic pleuropulmonary
infection: Clinical, radiologic, and bacteriologic correlations. J. Thoracic
Imaging. Accepted for publication.
3. Hill MK, Sanders CV: Comparison of beta-lactamase inhibitors. In: Therapeutic
Implications of Treatment with Beta-Lactamase Inhibitor Combinations , Neu HC (ed.). In Preparation.
4. Hill MK, Sanders CV: Comparison of beta-lactamase inhibitors. PharManual . In press.
5. Hilton CH, Fisher WP, Lopez-S A, Sanders CV: A Relative-value-based system
for quantification of faculty productivity: a simple, adjustable, weighted
system for calculating faculty productivity in teaching, research,
administration, and patient care. Academic Medicine . In press.
6. Hill MK, Sanders CV: Rash and fever. In: Infectious Diseases in
Critical Care Medicine , B. Cunha, ed. New
York: Marcel Dekker, Inc. In press.
7. Hill MK, Sanders CV: Cutaneous tuberculosis. In: Schlossberg D, ed. Tuberculosis , 4th ed. Philadelphia, PA, W.B. Saunders. In
preparation.
8. Hill MK, Sanders CV: Tuberculosis and pregnancy. In: Mead PB, Hager WD, Faro
S, eds. Infection Protocols for Obstetrics and Gynecology , 2nd ed. Montvale, NJ: Medical Economics. In press.
9. Hill MK, Sanders CV: Skin/soft tissue infections. Critical Care
Clinics on Infections in Critical Care . In
press.
10. Hill MK, Sanders CV: Cutaneous manifestations of infectious diseases.
Postgraduate Medicine. In preparation.
11. Hilton CW, Fisher WP, Sanders CV. A relative-value-based system to
quantitate faculty performance (abstract). Association of Program Directors in
Internal Medicine, submitted for publication.
12. Fisher WP, Vial R, Sanders CV. Removing rater effects from medical
clerkship evaluations (abstract). Academic Medicine . Accepted for publication.
13. Aldridge KS, Ashcraft DS, O'Cain P, Sanders CV, Janney A, Brown W,
Silberman R, Pankey G. A multicenter study of the prevalence and susceptibility
patterns of isolates of Streptococcus pneumoniae with reduced susceptibility to penicillin G in
Louisiana. Submitted for publication.
Abstracts and Preliminary Notes
1. Sanders CV, Luby JP, Johanson WG, Barnett JA, Sanford JP: An outbreak of
nosocomial infections due to Serratia marcescens traced to
contaminated inhalation-therapy medication. Abstract No. 150. J Lab Clin Med
74:1005, 1969.
2. Gilbert DN, Kutscher E, Sanders CV, Luby JP, Barnett JA, Sanford JP: The
apparent emergence of non-nosocomial/nosocomial wound infections: A study of
tornado casualties. J Lab Clin Med
76:999, 1970.
3. Sanders CV, Luby JP, Sanford JP: Suppression of interferon response in
uremic lymphocytes. Clin Res
18:446, 1970.
4. Repath F, Sanders CV, Dascomb HE: An agar plate capillary rod method for
testing antibiotic sensitivity of bacteria. Clin Res 20:83, 1972.
5. Lewis AC, Sanders CV, Mickal A, Redmond K, Torres J: Anaerobic microflora of
the endocerivx in healthy women and women with abnormal papanicolaou (Pap)
smears. South Central Branch of American Society for Microbiology, Hattiesburg,
Mississippi, October 11-12, 1974.
6. Sanders CV, Mickal A, Lewis AC, Torres J: Anaerobic flora of the endocervix
in women with normal versus abnormal papanicolaou (Pap) smears. Clin
Res 23:30A, 1975.
7. Sanders CV: Localization of site of urinary tract infection by detection of
antibody-coated bacteria in urine. South Central Branch of American Society for
Microbiology, New Orleans, Louisiana, March 21, 1975.
8. Hanna BJ, Sanders CV, Lewis AC, Williams WL, Sands ML: Treatment
of anaerobic infections with metronidazole. Sixteenth Interscience Conference
on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October 27-29,
1976.
9. Rojas M, Williams WL, Jones RJ, Taylor S, Sanders CV, Dascomb HE, Boudreaux
V: Experience with Mycobacterium kansasii
infection occurring in employees of a large general hospital. Sixteenth
Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago,
Illinois, October 27-29, 1976.
10. Burlington DB, Sanders CV: The effects of aspirin and prostaglandins on
lymphocyte interferon production. Sixteenth Interscience Conference on
Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October 27-29, 1976.
11. Bracis R, Sanders CV, Kimbrough R, Gilbert DN: Methicillin hemorrhagic
cystitis. Sixteenth Interscience Conference on Antimicrobial Agents and
Chemotherapy, Chicago, Illinois, October 27-29, 1976.
12. Sands M, Torres J, Sanders CV: In vitro sensitivity of Mycobacterium
marinum to minocycline and doxycycline.
Seventy-seventh Annual Meeting of the American Society for Microbiology, New
Orleans, Louisiana, May 8-13, 1977.
13. Ivens MS, Singleton B, Sanders CV: Experiences with skin testing of
hospital patients with antigenic substances derived from Sporothrix
schenckii . South Central Branch, American
Society for Microbiology, Jackson, Mississippi, October 21-22, 1977.
14. Singleton B, Ivens MS, and Sanders CV: Studies with skin testing of
hospital patients with antigenic substances derived from Sporothrix
schenckii . Minority Biomedical Support
Symposium, Atlanta, Georgia, March 27-29, 1978.
15. Torres-R J, Swenson RM, Hanna B, Lorber B, Sanders CV: Treatment of
anaerobic infections with ticarcillin, clinical and laboratory aspects.
Eighteenth Interscience Conference on Antimicrobial Agents and Chemotherapy,
Atlanta, Georgia, October 1-4, 1978.
16. Greenberg RN, Scalcini MC, Sanders CV: Cefamandole therapy for anaerobic
infections. Eighteenth Interscience Conference on Antimicrobial Agents and
Chemotherapy, Atlanta, Georgia, October 1-4, 1978.
17. Greenberg RN, Sanders CV, Lewis AC, Shaik LM: Localization of urinary tract
infection in the adult non-pregnant female. Clin Res 26:769A, 1978.
18. Moss SW, Sanders CV: Adherence of Escherichia coli to human vaginal cells mediated by mannose receptors
in women with recurrent urinary tract infection. Clin Res 26:770A, 1978.
19. Singleton B, Ivens MS, Sanders CV: Cutaneous hypersensitivity to
sporotrichin in hospital patients and other population groups. VII Congress of
the International Society for Human and Animal Mycology, Jerusalem, Israel,
March 11-16, 1979.
20. Sanders CV, Hanna BJ, Lewis AC, Scalcini M: The use of metronidazole in the
treatment of anaerobic pleuropulmonary infections. The Second International
Metronidazole Conference, Geneva, April 25-27, 1979.
21. Sanders CV, Shaik LM, Marier RL, Lehmann HP: Rapid assay of gentamicin in
serum by the enzyme multiplied immunoassay technique (EMIT). Nineteenth
Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston,
Massachusetts, October 1-5, 1979.
22. Greenberg RN, Sanders CV, Shaik LM, Marier RL, Lewis AC, Moise P: Single
dose therapy of urinary tract infections with cefaclor. Clin Res 27:751A, 1979.
23. Torres-R JR, Stratton CW, Sanders CV, Horsman TA, Hawley HB, Dascomb HE,
Vial LJ: Candidal suppurative peripheral thrombophlebitis. Clin Res 27:754A, 1979.
24. Sande MA, Korzeniowski OM, Endocarditis Collaborative Group, UVA Medical
School, Charlottesville, VA: Comparison of nafcillin (N) with nafcillin +
gentamicin (NG) in the treatment of addicts with S. aureus endocarditis. Nineteenth Interscience Conference on
Antimicrobial Agents and Chemotherapy, October 1-5, 1979.
25. Palmisano B, Marier RL, Pan YJ, Bernstein D, Sanders CV, Ragan FA, Saum R:
Stat gentamicin levels in premature infants by latex agglutination inhibition.
Conference of the American Society of Microbiology, September 1980.
26. LeGrand P, Bordelon JY, Gewin WC, Sanders CV: The telescoping plugged
catheter in suspected anaerobic infections: A controlled series. American
Thoracic Society/American Lung Association Annual Meeting, Washington, DC. Am
Rev Resp Dis 121:157, 1980.
27. Marier RL, Sanders CV: Piperacillin versus carbenicillin in the therapy of
severe infections. Twentieth Interscience Conference on Antimicrobial Agents
and Chemotherapy, New Orleans, Louisiana, September 22-24, 1980.
28. Greenberg RN, Sanders CV, Marier RL, Shaik LM, Moise P, Lewis AC:
Single-dose therapy of urinary tract infection with cefaclor. Twentieth
Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans,
Louisiana, September 22-24, 1980.
29. Zide MF, Sanders CV, Marier RL, Scalcini MS: Treatment of hospitalized
patients with severe odontogenic infections with cefuroxime. Twentieth
Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans,
Louisiana, September 22-24, 1980.
30. Sanders CV, Shaik LM, Marier RL, Lehmann HP: Rapid assay of gentamicin in
serum by the enzyme multiplied immunoassay technique. Proceedings of the
Eleventh International Congress of Chemotherapy, October 1-5, 1980.
31. Aldridge KE, Sanders CV, Marier RL: Comparison of the susceptibility of
anaerobic bacteria to various beta-lactam antibiotics. 81st Annual Meeting of
the American Society for Microbiology, Dallas, Texas, March 1-6, 1981.
32. Martin DA, Sanders CV: N-formimidoyl thienamycin (MK0787): In vitro
activity against anaerobes. Annual Meeting of the American Society for
Microbiology, Dallas, Texas, March 1-6, 1981.
33. Sanders CV: Piperacillin vs carbenicillin in the therapy of serious
infections. Problem Pathogens and Serious Infections: Management with
Piperacillin, Florence, Italy, July 19, 1981.
34. Marier RL, Sanders CV, Williams W, Derks F, Faro S, Dabezies E, Aldridge K:
Piperacillin vs carbenicillin in the therapy of severe infections. Twelfth
International Congress of Chemotherapy, Florence, Italy, July 19-24, 1981.
35. Marier RL, Faro S, Sanders CV, Williams W, Derks F, Aldridge K: Moxalactam
in the therapy of serious infections. Twelfth International Congress of
Chemotherapy, Florence, Italy, July 19-24, 1981.
36. Emison JW, Zide MF, Sanders CV: Treatment of fifty hospitalized patients
with severe odontogenic infections with cefuroxime. Sixty-third Annual Meeting,
American Association of Oral and Maxillofacial Surgeons, Washington, DC,
September 18-22, 1981.
37. Martin DA, Aldridge KE, Janney A, Sanders CV, Marier RL: In vitro
sensitivity patterns of Bacteroides fragilis to fifteen antimicrobial agents and occurrence of
beta-lactamase production. American Society for Microbiology, South Central
Branch, New Orleans, Louisiana, October 23-24, 1981.
38. Levison ME, ALA Collaborative Group (including CV Sanders): Penicillin (P)
vs clindamycin (C) treatment of anaerobic lung abscess (ALA). Twenty-first
Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago,
Illinois, November 4-6, 1981.
39. Chambers HF, Korzeniowski OM, Sande MA, National Collaborative Endocarditis
Study Group (including CV Sanders): Clinical manifestations of Staphylococcus
aureus endocarditis. Twenty-first
Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago,
Illinois, November 4-6, 1981.
40. Dismukes WE, Graybill JR, Steven DA, Shadomy S, Cloud C, Horton R,
Cryptococcal Meningitis Study Group (including CV Sanders): Phase II studies on
ketoconazole (K). Twenty-first Interscience Conference on Antimicrobial Agents
and Chemotherapy, Chicago, Illinois, November 4-6, 1981.
41. Espinel-Ingroff A, Shadomy S, Porter D, Steltz M, Dismukes WE, the CMSC
Group (including CV Sanders): Ketoconazole: Serum levels as determined by
bioassay (BA) and HPLC. Twenty-first Interscience Conference on Antimicrobial
Agents and Chemotherapy, Chicago, Illinois, November 4-6, 1981.
42. Shadomy S, Yu HP, White SC, Dismukes WE, CMCS Group (including CV Sanders):
Ketoconazole: Susceptibility testing of clinical isolates of pathogenic fungi.
Twenty-first Interscience Conference on Antimicrobial Agents and Chemotherapy,
Chicago, Illinois, November 4-6, 1981.
43. Marier RL, Aldridge KE, Sanders CV: The role of anaerobes in sinus and
middle ear infection: implications for the future. First United States
Metronidazole Conference, Tarpon Springs, Florida, February 19-21, 1982.
44. Sanders CV, Aldridge KE, Marier RL: Diagnosis of anaerobic infections.
First United States Metronidazole Conference, Tarpon Springs, Florida, February
19-21, 1982.
45. Marier RL, Aldridge KE, Martin D, Derks F, Williams W, Janney A, Sanders
CV: Thienamycin vs cefazolin in vivo. 22nd Interscience Conference on
Antimicrobial Agents and Chemotherapy, Miami, Florida, October 4-6, 1982.
46. Stith HD, Zide MF, Sanders CV, Aldridge KE, Marier RL: Parenteral and oral
cyclacillin in treatment of mild to severe maxillofacial infections. 64th
Annual Meeting of the American Association of Oral and Maxillofacial Surgeons,
Atlanta, Georgia, October 22-25, 1982.
47. Aldridge KE, Bednar NM, Marier RL, Sanders CV: Comparison of the
sensitivity of coagulase-negative staphylococcal species to various
antibiotics. American Society for Microbiology, 83rd Annual Meeting, New
Orleans, Louisiana, March 6-11, 1983.
48. Pepper L, Zide MF, Sanders CV, Marier RL: Intravenous and oral cyclacillin
in anaerobic maxillofacial infections. 65th Annual Meeting of the American
Association of Oral and Maxillofacial Surgeons, Las Vegas, Nevada, 1983.
49. Sanders CV, Marier RL: Penetration of sulbactam (CP-45, 899) into human
cerebrospinal fluid. 13th International Congress of Chemotherapy, Vienna,
Austria, August 28-September 2, 1983.
50. Aldridge KE, Sander CV, Faro S, Marier RL: Comparison of the in vitro
activity of azlocillin and mezlocillin with other antibiotics against clinical
isolates of Bacteroides fragilis, B. melaninogenicus , and B. bivivus . 13th International Congress of Chemotherapy,
Vienna, Austria, August 28-September 2, 1983.
51. Marier RL, McCloskey RV, Dickinson G, Sanders CV, Hoffman T, Gutterman D,
Aldridge KE: Comparative clinical trial of
N-formimidoyl-thienamycin-dehydropeptidase inhibitor (MS0787/0791) and
cefazolin. 13th International Congress of Chemotherapy, Vienna, Austria, August
28-September 2, 1983.
52. Marier RL, Sanders CV, Aldridge KE: Penetration of piperacillin into bone.
International Congress of Antimicrobial Agents and Chemotherapy, Las Vegas,
Nevada, October 24-27, 1983.
53. Marier RL, Sanders CV, Yu SL, Rounds O, Martin DH, Derks FW, Aldridge KE:
Single dose bacampicillin versus multidose amoxicillin therapy or urinary tract
infection. International Congress of Antimicrobial Agents and Chemotherapy, Las
Vegas, Nevada, October 24-27, 1983.
54. Janney A, Robichaux CJ, Marier RL, Sanders CV: Evaluation of the
antimicrobial removal device (ARD) for detection of bacteremia in patients
receiving antibiotics. International Congress of Antimicrobial Agents and
Chemotherapy, Las Vegas, Nevada, October 24-27, 1983.
55. Sanders CV, Marier RL, Aldridge KE, Derks FW, Martin DH:
Ticarcillin/clavulanic acid (TIC-CA) (BRL 28500) in the therapy of serious
infections. International Congress of Antimicrobial Agents and Chemotherapy,
Las Vegas, Nevada, October 24-27, 1983.
56. Soto LF, Sanders CV, Marier RL: Acinetobacter community-acquired pneumonia.
American College of Physicians Louisiana Chapter Associates Scientific Meeting,
New Orleans, Louisiana, November 19, 1983.
57. Aldridge KE, Sanders CV, Martin DH, Marier RL: In vitro comparison of B-lactam
antibiotics, alone and in combination with clavulanic acid and sulbactam and
effect of inoculum against clinical isolates of bacteria. Clin Res 31:879A, 1983.
58. Hanna BJ, Schechter FG, Sanders CV: Infective endocarditis (IE) in the
patient over 50. Southern Society for Clinical Investigation, New Orleans,
Louisiana, 1984.
59. Aldridge KE, Kogos C, Sanders CV, Marier RL: Comparison of commercial
serological kits with the tube coagulase test in the identification of Staphylococcus
aureus . 84th Annual Meeting of the
American Society for Microbiology, St. Louis, Missouri, March 4-9, 1984.
60. Aldridge KE, Sanders CV, Marier RL: Synergism and potentiation of ceftaxime
by desacetylcefotaxime in vitro
against strains of Bacteroides fragilis group. 84th Annual Meeting of the American Society for Microbiology,
St. Louis, Missouri, March 4-9, 1984.
61. Aldridge KE, Schiro D, Sanders CV, Marier RL: Ciprofloxacin (BAY09867):
Comparative activity with beta-lactam antibiotics and gentamicin against
aerobic gram positive and negative bacteria. 84th Annual Meeting of the
American Society for Microbiology, St. Louis, Missouri, March 4-9, 1984.
62. Aldridge KE, Sanders CV, Marier RL: The effect of inoculum on the in vitro
activity of beta-lactam antibiotics alone and in combination with clavulanic
acid and sulbactam against clinical isolates of bacteria. Charter Conference of
the Inter-American Society for Chemotherapy, Inc., St. Petersburg, Florida,
December 9-12, 1984.
63. Aldridge KE, Sanders CV, Faro S, Marier RL, Pastorek J: Comparison of the
in vitro activity of HR810, a new cephalosporin with other beta-lactam
antibiotics against Streptococcus agalactiae . Charter Conference of the Inter-American Society
for Chemotherapy, Inc., St. Petersburg, Florida, December 9-12, 1984.
64. deBoisblanc BP, Sanders CV: Actinomycosis: The Charity Hospital Experience.
American College of Physicians Louisiana Chapter Associates Scientific Meeting,
New Orleans, Louisiana, 1984.
65. Derks FW, Sanders CV: Choosing antibiotics for anaerobic infections.
Extracta Series, Acron Verlag Publishers, Berlin, Germany, l984.
66. Aldridge KE, Janney A, Sanders CV: Comparison of the activity of
coumermycin, ciprofloxacin, teicoplanin, and other non-B-lactam antibiotics
against clinical isolates of methicillin-resistant Staphylococcus
aureus from various geographical locations.
85th Annual Meeting of the American Society for Microbiology, Las Vegas,
Nevada, March 3-7, 1985.
67. Aldridge KE, Tsai L, Sanders CV: Comparative activity of ciprofloxacin (BAY
o 9867) with beta-lactam antibiotics and gentamicin, and the effect of inoculum
size, against aerobic gram positive and negative bacteria. 14th International
Congress of Chemotherapy, Kyoto, Japan, June 23-28, 1985.
68. Aldridge KE, Sanders CV: Increased in vitro anti-bacteroides activity of
cefotaxime: synergistic interaction of cefotaxime and desacetylcefotaxime. 14th
International Congress of Chemotherapy, Kyoto, Japan, June 23-28, 1985.
69. Aldridge KE, Pastorek JG, Faro S, Sanders CV: Significant changes in
genital flora in women receiving antibiotic prophylaxis for vaginal
hysterectomy: Comparison of cefoxitin, mezlocillin, and piperacillin. Annual
Meeting of the Infectious Disease Society of Obstetrics-Gynecology. Vancouver,
British Columbia, August, 1985.
70. Aldridge KE, Janney A, Sanders CV: Carumonam (Ro 17-2301), a new
monobactam: Comparison of in vitro activity with other broad spectrum
antibiotics. Twenty-fifth Interscience Conference on Antimicrobial Agents and
Chemotherapy, Minneapolis, Minnesota, September 29-October 2, 1985.
71. Verrette PR, Sanders CV: A brain abscess caused by Haemophilus
aphrophilus : A case report and review of
the literature. American College of Physicians Louisiana Chapter Associates
Scientific Meeting, New Orleans, Louisiana, 1985.
72. Aldridge KE, Sanders CV: Carumonam (RO 17-2301), a new monobactam: In vitro
synergistic interaction with aminoglycosides against P. aeruginosa,
S. marcescens, E. cloacae , and A.
caloaceticus . Annual Conference II of the
Inter-American Society for Chemotherapy, Inc., Tampa, Florida, December 8-11,
1985.
73. Grandon PW, Sanders CV: Group JK diphtheroid meningitis associated with
post-operative CSF leak. American College of Physicians Louisiana Chapter
Associates Scientific Meeting, New Orleans, Louisiana, 1985.
74. Aldridge KE, Janney A, Sanders CV: Cefamandole and methicillin-resistant Staphylococcus
aureus : True or false susceptibility
patterns? 86th Annual Meeting of the American Society for Microbiology,
Washington, DC, March 23-28, 1986.
75. Aldridge KE, Sanders CV: Pefloxacin, a new fluorinated quinolone
antibiotic: Comparison of in vitro activity to other broad spectrum
antibiotics. International Symposium on New Quinolones, Geneva, Switzerland,
July 17-19, 1986.
76. Sanders CV, Aldridge KE: Comparative in vitro activity of ciprofloxacin,
norfloxacin, ofloxacin, beta-lactam antibiotics, and gentamicin against aerobic
gram positive cocci and gram negative bacilli. International Symposium on New
Quinolones, Geneva, Switzerland, July 17-19, 1986.
77. Aldridge KE, Stratton CW, Weeks LP, Sanders CV: Bactericidal activity of
cefotaxime (cefotax), cefoxitin (cefox), ceftizoxime (ceftiz), chloramphenicol
(chloro), clindamycin (clinda), and metronidazole (metro) using kill-kinetic
studies against Bacteroides fragilis
group (B.F.gr.) isolates. IXth International Congress of Infectious and
Parasitic Diseases, Munich, Germany, July 20-26, 1986.
78. Aldridge KE, Stratton CW, Sanders CV: The role of desacetylcefotaxime
(des-cefotax) in the potentiation of cefotaxime (cefotax) against Bacteroides
species: Comparison of in vitro versus in vivo studies. IXth International
Congress of Infectious and Parasitic Diseases, Munich, Germany, July 20-26,
1986.
79. Aldridge KE, Sanders CV: Comparative in vitro activity of ciprofloxacin,
ofloxacin and norfloxacin with beta-lactam antibiotics against aerobic gram
positive cocci and gram negative bacilli. IXth International Congress of
Infectious and Parasitic Diseases, Munich, Germany, July 20-26, 1986.
80. Aldridge KE, Stratton CW, Weeks LP, Sanders CV: Synergistic bactericidal
activity of cefotaxime and desacetyl-cefotaxime in combination versus the
antibiotics alone against strains of Bacteroides fragilis group. IXth International Congress of Infectious and
parasitic Diseases, Munich, Germany, July 20-26, 1986.
81. Aldridge KE, Sanders CV: Susceptibility testing of anaerobes:
Medium-dependent variations in results. 26th Interscience Conference on
Antimicrobial Agents and chemotherapy, New Orleans, Louisiana, September, 1986.
82. Aldridge KE, Sanders CV: Comparison of the in vitro activity of BMY-28100,
a new cephalosporin, with other oral antibiotics. 26th Interscience Conference
of Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September
1986.
83. Aldridge KE, Sanders CV: Variations in results and interpretation of
susceptibilities of Bacteroides fragilis group isolates which are methodology
dependent. 3rd Pan American Congress of Infectious Diseases and Chemotherapy,
San Juan, Puerto Rico, December 1986.
84. Sanders CV, Besch CL, Zide MF, Marier RL, Aldridge KE, Derks FW:
Ampicillin/sulbactam versus clindamycin for maxillofacial infections.
Therapeutic Considerations in the Management of Infectious Diseases: Today and
Tomorrow. Montreux, Switzerland, July 1987.
85. Fan Y-D, Pastorek JG, Sanders CV: Listeriosis as an obstetric complication
in the immunocompromised patient. American College of Obstetrics & Gynecology,
District VII Annual Meeting, Little Rock, Arkansas, October 11-15, 1986.
86. Aldridge KE, Valainis G, Sanders CV: Comparison of the activity of
ciprofloxacin and 23 other antimicrobial agents against clinical strains of Chromobacterium
violaceum . 27th Interscience Conference on
Antimicrobial Agents and Chemotherapy, New York, New York, October 4-7, 1987.
87. Aldridge KE, Wexler HM, Sanders CV, Finegold SM: In vitro antibiograms of Bacteroides
fragilis group isolates: Differences in
resistance rates in two institutions due to susceptibility methodology. 27th
Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New
York, October 4-7, 1987.
88. Bedsole G, Wallace RJ Jr., Sanders CV, Steele LC, Graham DR: Activity of
ciprofloxacin and ofloxacin against Mycobacterium fortuitum with emergence of drug resistance during therapy.
27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New
York, New York, October 4-7, 1987.
89. Sanders CV: Beta-lactamase inhibitor in the treatment of post C-section
endomyometritis. Symposium on Beta-lactamase Inhibition: Therapeutic
Implications in Obstetrics and Gynecology, Baylor College of Medicine, Houston,
November 12-15, 1987.
90. Hoadley DJ, Sanders CV, Schlievert PM: Toxic shock-like syndrome due to Streptococcus
pyogenes in the setting of soft tissue
infection and bacteremia. Southern Section, American Federation for Clinical
Research, New Orleans, Louisiana, February 3-5, 1988.
91. Sanders CV, Besch CL, Zide MF, Marier RL, Aldridge KE, Derks FW:
Sulbactam/ampicillin versus clindamycin for maxillofacial infections. Southern
Section, American Federation for Clinical Research, New Orleans, Louisiana,
February 3-5, 1988.
92. Sanders CV, Aldridge KE, Yu SL, Derks FW: Trimethoprim/sulfamethoxazole
(TMP/SMX) vs cephalosporin in adult women with community-acquired acute
pyelonephritis (P). Southern Section, American Federation for Clinical
Research, New Orleans, Louisiana, February 3-5, 1988.
93. Aldridge KE, Wall JH, Facklam R, Reller LB, Janney A, Sanders CV:
Identification of viridans streptococci by three commercial systems: Comparison
with the reference CDC method. 88th Annual Meeting of the American Society for
Microbiology, Miami Beach, Florida, May 8-13, 1988.
94. Aldridge KE, Henderberg A, Schiro DD, Sanders CV: Comparison of the in
vitro activity of broad-spectrum cephalosporin-cephamycin and penicillin
antimicrobial agents against clinical strains of the Bacteroides
fragilis group: Correlation of
cross-resistance and B-lactamase production. 88th Annual Meeting of the
American Society for Microbiology, Miami Beach, Florida, May 8-13, 1988.
95. Henderberg A, Aldridge KE, Sanders CV: Comparison of the in vitro activity
of SC-47111 (NY-198), a new fluoroquinolone, to other antimicrobial agents
against staphylococci, streptococci, Haemophilus influenzae , and Branhamella catarrhalis . 88th Annual Meeting of the American Society for
Microbiology, Miami Beach, Florida, May 8-13, 1988.
96. Aldridge KE, Henderberg A, Sanders CV: SC-47111 (NY-198), a new fluorinated
quinolone: Comparison of the in vitro activity with other broad spectrum
antimicrobials against Enterobacteriaceae acinetobacter and Pseudomonas aeruginosa . 6th Mediterranean Congress of Chemotherapy,
Taormina, Sicily, Italy, May 22-27, 1988.
97. Aldridge KE, Henderberg A, Sanders CV: Lomefloxacin: Comparison of in vitro
activity with other broad-spectrum antimicrobials against gram-positive and
-negative bacteria. 2nd International Symposium on New Quinolones, Geneva, Switzerland,
August 25-27, 1988.
98. Aldridge KE, Henderberg A, Sanders CV: Mutational frequency rates of
gram-positive and -negative bacteria to lomefloxacin and other quinolones. 2nd
International Symposium on New Quinolones, Geneva, Switzerland, August 25-27,
1988.
99. Aldridge KE, Henderberg A, Sanders CV, Multicenter Study Group: A
Multicenter study of resistance and cross-resistant patterns of the Bacteroides
fragilis group and various species.
International Symposium on Anaerobic Bacteria and Bacterial Infections, Monte
Carlo, September 25-28, 1988.
100. Aldridge KE, Henderberg A, Sanders CV: In vitro activity of lomefloxacin,
a new difluoroquinolone, compared to other broad-spectrum antimicrobials. 28th
Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles,
California, October 1988.
101. Aldridge KE, Henderberg A, Schiro DD, Sanders CV: Comparison of resistance
and cross-resistance rates of B. fragilis group isolates to ceftizoxime, cefoxitin, cefotetan, cefotaxime,
ceftriaxone, piperacillin, and clindamycin. Third European Congress on
Anaerobic Bacteria and Infections, Munich, Germany, March 1989.
102. Aldridge KE, Henderberg A, Schiro DD, Sanders CV: Enhanced in vitro
activity against Bacteroides fragilis species of ticarcillin/clavulanic acid and amoxicillin/clavulanic
acid: Comparison to the activity of other beta-lactams, clindamycin and
metronidazole. Third European Congress on Anaerobic Bacteria and Infections,
Munich, Germany, March 1989.
103. Aldridge KE, Henderberg A, Schiro DD, Sanders CV: In vitro activity of
ampicillin and cefoperazone alone and in combination with sulbactam against the
B. fragilis group, B.
bivivus , and B. disiens . Third European Congress on Anaerobic Bacteria and
Infections, Munich, Germany, March 1989.
104. Henderberg A, Aldridge KE, Sanders CV: The effect of subinhibitory
concentrations of lomefloxacin and other quinolones on in vitro resistance
levels among clinical strains of bacteria. 89th Annual Meeting of the American
Society for Microbiology, New Orleans, Louisiana, May 1989.
105. Gebbia K, Aldridge KE, Sanders CV: Comparison of the in vitro activity of
oral antimicrobials against clinical strains of Gardnerella vaginalis . 89th Annual Meeting of the American Society for
Microbiology, New Orleans, Louisiana, May 1989.
106. Schiro DD, Aldridge KE, Sanders CV: Disk-elution susceptibility testing of
anaerobes: A re-examination of testing parameters. 89th Annual Meeting of the
American Society for Microbiology, New Orleans, Louisiana, May 1989.
107. Risi G, Gaumer R, Weeks S, Leete J, Sanders CV: The risk of exposure to
human immunodeficiency virus among health care workers (HCW) at a southern U.S.
urban hospital. Vth International Conference on AIDS, Montreal, Canada, June
1989.
108. Aldridge KE, Gebbia K, Henderberg A, Pastorek J, Sanders CV: In vitro
activity of old and new beta-lactams compared to that of clindamycin,
doxycycline, and metronidazole against anaerobes isolated from OB-GYN
specimens. Annual Meeting of the Infectious Disease Society for
Obstetrics-Gynecology, Quebec, Canada, August 1989.
109. Gorelick K, Jacobs R, Chmel H, Trenholme G, Greenman R, The Xoma Sepsis
Study Group, Xoma Corp.: Efficacy results of a randomized multicenter trial of
E5 antiendotoxin monoclonal antibody in patients with suspected gram-negative
sepsis. Twenty-Ninth Interscience Conference on Antimicrobial Agents and
Chemotherapy, Houston, Texas, September 17-20, 1989.
110. Martin MA, Wenzel RP, Gorelick KJ, Xoma Sepsis Study Group, University of
Maryland: Prospective national study of gram-negative bacterial (GNB)
sepsis--natural history in the 1980s. Twenty-Ninth Interscience Conference on
Antimicrobial Agents and Chemotherapy, Houston, Texas, September 17-20, 1989.
111. Aldridge KE, Henderberg A, Sanders CV: In vitro activity of
beta-lactam/beta-lactamase inhibitor (B-L/B-L-I) combinations against B.
fragilis , group isolates compared to
cefoxitin (FOX) and clindamycin (CLIN). Twenty-Ninth Interscience Conference on
Antimicrobial Agents and Chemotherapy, Houston, Texas, September 17-20, 1989.
112. Reynaud P, Goodfellow K, Svec F, Sanders CV: Porphyria cutanea tarda as
initial presentation in acquired immune deficiency syndrome: Two case reports.
Southern Section American Federation for Clinical Research, New Orleans,
Louisiana, January 17-19, 1990.
113. Aldridge KE, Schiro DD, Sanders CV: An in vitro study of the activity of
fleroxacin and metronidazole alone and in combination against mono- and
polymicrobial inocula. American Society for Microbiology Annual Meeting,
Anaheim, California, May 13-17, 1990.
114. Hill MK, Sanders CV: Treatment of the brain abscess. Ochsner
Clinic Reports on Serious Hospital Infections
5(1):1-8, 1990.
115. MacIntyre NR, Emmanuel G, Wedel NI, Gorelick KJ, Xoma Sepsis Study Group:
E5 antibody improves outcome from multi-organ failure in survivors of
gram-negative sepsis. Society for Critical Care Medicine, Washington, D.C., May
22-26, 1991.
116. Aldridge KE, Pastorek J, Martin D, Sanders CV, Espinosa T: A randomized,
blinded comparison of cefotetan and cefoxitin for the treatment of
post-caesarean infection. Annual Meeting of the Infectious Disease Society for
Obstetrics-Gynecology, Hamilton, Bermuda, August 1-4, 1991.
117. Sanders CV, Aldridge KE: Treatment of anaerobic infections: l992. 2nd
International Symposium on Anaerobic Bacteria and Infections, Vienna, Austria,
March 3-12, 1992.
118. Sanders CV: Treatment of anaerobic infections with
tazobactam/piperacillin. Biennial Conference on Chemotherapy of Infectious
Diseases and Malignancies, Prague Czechoslovakia, August 30-September l, l992.
119. Sanders CV: Piperacillin/tazobactam in the treatment of lower respiratory
tract infections. The 6th European Congress on Intensive Care Medicine 1992.
Barcelona, Spain, October 26-31, 1992.
120. Marier RL, Sanders CV, Aldridge KE: Treatment of mixed surgical
infections. World Congress of Surgery, Sao Paulo, Brazil.
121. Sanders CV: Role of Piperacillin/tazobactam in the treatment of
polymicrobial gynecological and skin and skin-structure infections: review of
worldwide clinical trials. The 18th International Congress of Chemotherapy;
Stockholm, Sweden; June 27-July 2, 1993.
122. Aldridge KE, Schiro DD, Sanders CV: In vitro activity of various ß-lactam
and ß-lactam/ß-lactamase inhibitor combinations against ß-lactamase-positive
and -negative non-Bacteroides fragilis group. The 33rd Interscience Conference on Antimicrobial Agents and
Chemotherapy, New Orleans, Louisiana, October 1993.
123. Aldridge KE, Schiro DD, Sanders CV: Louisiana hot sauce versus Vibrio species: never eat oysters without it? The 33rd
Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans,
Louisiana, October 1993.
124. Aldridge KE, Schiro DD, Sanders CV: Susceptibility of non-Bacteroides anaerobes to ß-Lactam, ß-Lactam/ß-Lactamase
inhibitor combinations, and metronidazole. 94th General Meeting of the American
Society for Microbiology, Las Vegas, Nevada, May 23-27, 1994.
125. Aldridge K, Schiro D, Pastorek J, Sanders CV: Comparison of the in vitro
susceptibility of anaerobic bacteria associated with female pelvic infection to
old and new antimicrobial agents. 1994 Annual Meeting of the Infectious
Diseases Society for Obstetrics and Gynecology, Monterey, California, August
3-6, 1994.
126. Hilton CW, Sanders, CV: ARRelative-value-based system to quantitate
faculty performance. American Federation for Clinical Research/Southern Society
for Clinical Investigation 1996 Southern Section Meetings, New Orleans, January
31, February 2, 1996. J Invest Med
44:43A, 1996.
127. Aldridge KE, O'Cain P, Ashcraft D, Sanders CV: Prevalence and distribution
of penicillin-resistant Streptococcus pneumoniae among strains endemic to Louisiana. 36th
Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans,
September 14-16, 1996.
128. Aldridge KE, Ashcraft D, O'Cain P, Sanders CV. The prevalence of
multiple-antibiotic-resistance among strains of Streptococcus
pneumoniae with reduced susceptibility to
penicillin G. J Invest Med
45:13A, 1997.